NCT01703169View on ClinicalTrials.gov

Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Severe Aplastic AnemiaVery Severe Aplastic AnemiaModerate Aplastic Anemia
Interventions
DRUG

Eltrombopag

Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count

Trial Locations (1)

84112

University of Utah, Salt Lake City

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Utah

OTHER